S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
Log in

NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

$15.44
+0.44 (+2.93 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$14.26
Now: $15.44
$16.07
50-Day Range
$4.71
MA: $6.08
$15.44
52-Week Range
$3.52
Now: $15.44
$17.48
Volume14.10 million shs
Average Volume1.16 million shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.25
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-744-2487

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$1.32 per share

Profitability

Net Income$-64,120,000.00
Net Margins-19,483.96%

Miscellaneous

Employees39
Market Cap$1.46 billion
Next Earnings Date3/17/2020 (Estimated)
OptionableOptionable

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.


Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to the consensus estimate of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

What price target have analysts set for AUPH?

7 brokerages have issued 1 year target prices for Aurinia Pharmaceuticals' shares. Their forecasts range from $11.00 to $30.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $20.33 in the next year. This suggests a possible upside of 31.7% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

Media headlines about AUPH stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Aurinia Pharmaceuticals.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 9,100,000 shares, an increase of 11.5% from the September 30th total of 8,160,000 shares. Based on an average daily trading volume, of 960,900 shares, the days-to-cover ratio is currently 9.5 days. Currently, 13.6% of the shares of the company are short sold. View Aurinia Pharmaceuticals' Current Options Chain.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), Array Biopharma (ARRY), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Cara Therapeutics (CARA), Synergy Pharmaceuticals (SGYP), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL) and Novavax (NVAX).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.05%), Stifel Financial Corp (0.05%), Virtu Financial LLC (0.02%), Patriot Financial Group Insurance Agency LLC (0.02%), Benjamin F. Edwards & Company Inc. (0.01%) and Tower Research Capital LLC TRC (0.01%).

Which major investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Virtu Financial LLC, Tower Research Capital LLC TRC, Patriot Financial Group Insurance Agency LLC, Benjamin F. Edwards & Company Inc. and Stifel Financial Corp.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $15.44.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $1.46 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]


MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  448 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  734
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel